Spots Global Cancer Trial Database for Biomarker in Tumor Tissue Samples From Patients With Rhabdomyosarcoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Biomarker in Tumor Tissue Samples From Patients With Rhabdomyosarcoma

Official Title: A Study to Assess and Quantify Surface Insulin-like Growth Factor I Receptor (IGF-IR) in Rhabdomyosarcoma (RMS) Tumor Tissue

Study ID: NCT01365962

Conditions

Sarcoma

Interventions

gene expression analysis

immunohistochemistry staining method

laboratory biomarker analysis

mass spectrometry

Study Description

Brief Summary: RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research trial studies biomarkers in tumor tissue samples from patients with rhabdomyosarcoma.

Detailed Description: OBJECTIVES: * To determine and quantify the degree of surface insulin-like growth factor I receptor (IGF-IR) expression in rhabdomyosarcoma (RMS) tumor tissue. * To assess the feasibility and validity of a mass spectrometry assay for IGF-IR expression on paraffin-embedded tumor tissue. OUTLINE: Paraffin-embedded tumor tissue slides are analyzed for insulin-like growth factor I receptor (IGF-1R) expression by mass spectrometry and correlated with the results obtained by IHC assay.